Dexbrompheniramine

# Disclaimer
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider.  WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery.  The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements.  WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
NOTE: Most over the counter (OTC) are not reviewed and approved by the FDA. However, they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

# Overview
Dexbrompheniramine is a antihistamine and alkylamine that is FDA approved for the treatment of rash, xerostomia, drowsiness, dizziness, nervousness and insomnia.   Common adverse reactions include .

# Adult Indications and Dosage

## FDA-Labeled Indications and Dosage (Adult)
- Temporarily relieves these symptoms due to hay fever (allergic rhinitis) or upper respiratory allergies:
- runny nose
- sneezing
- itching of the nose or throat
- itchy, watery eyes

## Off-Label Use and Dosage (Adult)

### Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Dexbrompheniramine in adult patients.

### NonGuideline-Supported Use
There is limited information regarding Off-Label NonGuideline-Supported Use of Dexbrompheniramine in adult patients.

# Pediatric Indications and Dosage

## FDA-Labeled Indications and Dosage (Pediatric)
There is limited information regarding FDA-Labeled Use of Dexbrompheniramine in pediatric patients.

## Off-Label Use and Dosage (Pediatric)

### Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Dexbrompheniramine in pediatric patients.

### NonGuideline-Supported Use
There is limited information regarding Off-Label NonGuideline-Supported Use of Dexbrompheniramine in pediatric patients.

# Contraindications
There is limited information regarding Contraindications of Dexbrompheniramine in pediatric patients.

# Warnings
- a breathing problem such as emphysema or chronic bronchitis
- glaucoma
- trouble urinating due to enlargement of the prostate gland

### Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers.=
- excitability may occur, especially in children
- may cause drowsiness
- avoid alcoholic drinks
- alcohol, sedatives, and tranquilizers may increase the drowsiness effect
- use caution when driving a motor vehicle or operating machinery
- If pregnant or breast-feeding, ask a health professional before use.
- Keep out of reach of children.
- In case of overdose, get medical help or contact a Poison Control Center right away.

# Adverse Reactions

## Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Dexbrompheniramine in the drug label.

## Postmarketing Experience
There is limited information regarding Postmarketing Experience of Dexbrompheniramine in the drug label.

# Drug Interactions
There is limited information regarding Drug Interactions of Dexbrompheniramine in pediatric patients.

# Use in Specific Populations

### Pregnancy
Pregnancy Category (FDA):
- Pregnancy Category
Pregnancy Category (AUS):
- Australian Drug Evaluation Committee (ADEC) Pregnancy Category
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Dexbrompheniramine in women who are pregnant.

### Labor and Delivery
There is no FDA guidance on use of Dexbrompheniramine during labor and delivery.

### Nursing Mothers
There is no FDA guidance on the use of Dexbrompheniramine with respect to nursing mothers.

### Pediatric Use
There is no FDA guidance on the use of Dexbrompheniramine with respect to pediatric patients.

### Geriatic Use
There is no FDA guidance on the use of Dexbrompheniramine with respect to geriatric patients.

### Gender
There is no FDA guidance on the use of Dexbrompheniramine with respect to specific gender populations.

### Race
There is no FDA guidance on the use of Dexbrompheniramine with respect to specific racial populations.

### Renal Impairment
There is no FDA guidance on the use of Dexbrompheniramine in patients with renal impairment.

### Hepatic Impairment
There is no FDA guidance on the use of Dexbrompheniramine in patients with hepatic impairment.

### Females of Reproductive Potential and Males
There is no FDA guidance on the use of Dexbrompheniramine in women of reproductive potentials and males.

### Immunocompromised Patients
There is no FDA guidance one the use of Dexbrompheniramine in patients who are immunocompromised.

# Administration and Monitoring

### Administration
- Oral

### Monitoring
There is limited information regarding Monitoring of Dexbrompheniramine in the drug label.

# IV Compatibility
There is limited information regarding IV Compatibility of Dexbrompheniramine in the drug label.

# Overdosage
There is limited information regarding Chronic Overdose of Dexbrompheniramine in the drug label.

# Pharmacology
There is limited information regarding Dexbrompheniramine Pharmacology in the drug label.

## Mechanism of Action

## Structure

## Pharmacodynamics
There is limited information regarding Pharmacodynamics of Dexbrompheniramine in the drug label.

## Pharmacokinetics
There is limited information regarding Pharmacokinetics of Dexbrompheniramine in the drug label.

## Nonclinical Toxicology
There is limited information regarding Nonclinical Toxicology of Dexbrompheniramine in the drug label.

# Clinical Studies
There is limited information regarding Clinical Studies of Dexbrompheniramine in the drug label.

# How Supplied

## Storage
There is limited information regarding Dexbrompheniramine Storage in the drug label.

# Images

## Drug Images

## Package and Label Display Panel
The packaging below represents the labeling currently used.
Principal display panel and side panel for 60 tablets label:
NDC 50991-783-60
ALA-HIST IR
2 mg Tablets
Antihistamine
Each tablet contains:
Dexbrompheniramine Maleate.........2 mg
60 Tablets
Usual Dosage:  See product foldout for full
prescribing information
Tamper evident by foil seal under cap.  Do not
use if foil seal is broken or missing.
KEEP THIS AND ALL DRUGS OUT OF 
REACH OF CHILDREN. 
Store at controlled room temperature 15-30C
(59-86F).
Manufactured for:
Poly Pharmaceuticals
Quitman, MS  39355
Rev. 02/12

# Patient Counseling Information
There is limited information regarding Patient Counseling Information of Dexbrompheniramine in the drug label.

# Precautions with Alcohol
- Alcohol-Dexbrompheniramine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

# Brand Names

# Look-Alike Drug Names
There is limited information regarding Dexbrompheniramine Look-Alike Drug Names in the drug label.

# Drug Shortage Status

# Price